文献速递外周动脉疾病

心脏功能对新一代器械行股腘动脉腔内治疗的外周动脉疾病患者通畅性丧失的影响

Impact of Cardiac Function on Loss of Patency in Patients With Peripheral Artery Disease Presenting the Femoropopliteal Lesions Endovascularly Treated With New-Generation Devices.
PubMed 文献 · J Endovasc Ther · 2022-01-20

回顾性分析416例患者547处股腘动脉病变,均使用新一代股腘动脉专用器械行腔内治疗。多因素分析显示,超声心动图评估的每搏输出量降低(HR=0.99,95%CI 0.97-0.99,p=0.03)、慢性心力衰竭(HR=1.76,95%CI 1.05-2.97,p=0.03)及较小的远端参考血管直径(HR=0.73,95%CI 0.55-0.97,p=0.03)与12个月一期通畅性丧失显著相关。

要点

  • 每搏输出量降低、慢性心力衰竭及较小远端参考血管直径与12个月一期通畅性丧失显著相关。
  • 病变长度(HR=1.01,p=0.33)和慢性完全闭塞(HR=0.92,p=0.70)与通畅性丧失无统计学显著关联。
  • 总体12个月一期通畅率为80.0±1.8%。

核心结论

  • 以每搏输出量降低和慢性心力衰竭体现的心脏功能以及较小的远端参考血管直径,与新一代器械行股腘动脉腔内治疗的外周动脉疾病患者12个月一期通畅性丧失显著相关。

研究设计与样本

  • 回顾性研究纳入416例患者共547处股腘动脉病变,均使用新一代股腘动脉专用器械行腔内治疗,时间范围为2012年6月至2019年5月。
  • 病变特征包括慢性肢体威胁性缺血44%、TASC II C/D级病变61%、慢性完全闭塞37%、支架内再狭窄13%、累及腘动脉病变45%。
  • 患者平均年龄75±9岁,男性69%,糖尿病62%,血液透析33%。
  • 使用器械包括无聚合物紫杉醇洗脱支架186处、支架移植物119处、含氟聚合物紫杉醇洗脱支架29处、编织支架17处、药物涂层球囊196处。
  • 心脏功能采用超声心动图评估,主要结局为一期通畅性,定义为双功超声评估的收缩期峰值流速比(PSVR)≤2.5。

主要发现

  • 总体12个月一期通畅率为80.0±1.8%。
  • 多因素分析显示,超声心动图评估的每搏输出量降低与12个月一期通畅性丧失显著相关(HR=0.99,95%CI 0.97-0.99,p=0.03)。
  • 慢性心力衰竭与12个月一期通畅性丧失显著相关(HR=1.76,95%CI 1.05-2.97,p=0.03)。
  • 较小的远端参考血管直径与12个月一期通畅性丧失显著相关(HR=0.73,95%CI 0.55-0.97,p=0.03)。
  • 病变长度(HR=1.01,95%CI 0.99-1.03,p=0.33)和慢性完全闭塞(HR=0.92,95%CI 0.61-1.40,p=0.70)与12个月一期通畅性丧失无统计学显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The current study sought to investigate the impact of cardiac condition on loss of patency after endovascular therapy (EVT) using new-generation devices for femoropopliteal (FP) lesions. MATERIALS AND METHODS: We retrospectively studied 547 lesions (chronic limb-threatening ischemia: 44%, TASC II C/D lesion: 61%, chronic total occlusion: 37%, in-stent restenosis: 13%, involving popliteal arterial lesion: 45%) belonging to 416 patients (average age: 75±9 years, male: 69%, diabetes mellitus: 62%, hemodialysis: 33%) who underwent EVT with new-generation FP-specific devices (polymer-free paclitaxel-eluting stent, n=186; stent graft, n=119; fluoropolymer-based paclitaxel-eluting stent, n=29; interwoven stent, n=17; drug-coated balloon, n=196) from June 2012 to May 2019. Cardiac function was evaluated using echocardiography. The primary outcome measure was primary patency, which was defined as free from peak systolic velocity ratio (PSVR) >2.5 assessed by duplex ultrasound. Predictors for loss of patency were evaluated using Cox proportional hazards regression analysis. RESULTS: Overall 12 primary patency were 80.0±1.8%. After the multivariate analysis, reduced stroke volume evaluated by echocardiography (hazard ratio [HR]=0.99, 95% confidence interval [CI]=0.97-0.99, p=0.03), chronic heart failure (HR=1.76, 95% CI=1.05-2.97, p=0.03), and a smaller distal reference vessel diameter (HR=0.73, 95% CI=0.55-0.97, p=0.03) were significantly associated with loss of 12-month primary patency, whereas lesion length (HR=1.01, 95% CI=0.99-1.03, p=0.33) and presence of chronic total occlusion (CTO; HR=0.92, 95% CI=0.61-1.40, p=0.70) were not statistically significant. CONCLUSION: The current study revealed that cardiac function represented by reduced stroke volume and presence of chronic heart failure as well as a smaller distal reference vessel diameter were significantly associated with loss of 12-month primary patency in patients with peripheral artery disease (PAD) presenting FP lesions endovascularly treated with new-generation devices.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Nakao S, Iida O, Hata Y, et al. Impact of Cardiac Function on Loss of Patency in Patients With Peripheral Artery Disease Presenting the Femoropopliteal Lesions Endovascularly Treated With New-Generation Devices. J Endovasc Ther. 2022. PMID: 35057659. doi:10.1177/15266028211070963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。